FDA accepts new drug application for Merck’s Doravirine/Islatravir

The FDA set a target action date of April 28, 2026, under the Prescription Drug User Fee Act

Pfizer and Astellas' Xtandi combo extends survival in early prostate cancer setting

Xtandi is approved in over 80 countries, including the U.S., EU, and Japan

Merck to present new research data across its HIV prevention and treatment pipeline at IAS 2025

Additional data will be presented on a once-weekly oral combination of islatravir and ulonivirine (ISL/ULO) for HIV-1 treatment

Seeds of Innocence launches Asia’s first at-home IVF platform

India’s fertility rate has dropped to 1.9, below the replacement level of 2.1

CARE Hospitals, Hitech City introduces AI-powered robotic surgery system

The Stryker Mako Robotic System uses artificial intelligence to improve surgical accuracy with real-time guidance, personalized planning, and precise execution

Duke Street Bio receives FDA fast track designation for PARP1-selective inhibitor with CNS activity

Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need

AB Science receives FDA and EMA authorization for phase 3 Trial of prostate cancer treatment

Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments

EMA and HMA to strengthen Anti-D Immunoglobulin supply chain

These medicines are essential in preventing RhD immunisation during pregnancy

Veerhealth Care enters into contract manufacturing agreement

Commercial production is expected to begin soon

Nectar Lifesciences sell API and formulations business to Ceph Lifesciences for Rs. 1,270 Cr